37 results about "XRCC1 Gene" patented technology

The invention provides a 5-fluorouracil drug sensitivity gene chip detection kit, which can be used to parallelly and economically detect genes related to 5-fluorouracil drug sensitivity. The kit comprises an extraction solution, a hybridization buffer solution, a washing liquor, an amplifying solution, Taq enzyme and a gene chip, the amplifying solution contains a primer for amplifying four genes containing mutant sites, and the four genes include a DPD gene containing IVS14 A / G mutant sites, a GSTPi gene containing Ile105Val mutant sites, an MTHFR gene containing C677T mutant sites, and an XRCC1 gene containing Arg399Glu mutant sites. The 5 fluorouracil is a first-line anti-tumor chemotherapeutic drug, and the detection kit can be used for detecting the four gene mutation conditions sensitive to the 5 fluorouracil drug.

The invention discloses a reagent kit for detecting lung cancer susceptibility, comprising a common component for fluorescence quantitative PCR detection, and a specific primer pair and a specific fluorescent probe which detect the NO. rs1136410 SNP site of PARP1 gene, the NO. rs1048943 SNP site of CYP1A1 gene, the NO. rs25487 SNP site of XRCC1 gene, the NO. rs13181 SNP site of ERCC2 gene and the NO. rs1799793 SNP site of ERCC2 gene at the same time. The reagent kit can predict the lung cancer susceptibility of individual through detecting the SNPs site genotype of PARP1 gene, CYP1A1 gene, XRCC1 gene and ERCC2 gene of individual at the same time.

The invention discloses a method for DNA damage repair capacity inheritance risk assessment which is characterized in that: by simultaneously detecting and analyzing carrying types of a PARP1 gene, an XRCC1 gene, an ERCC2 and an SNPs locus gene of an individual, the method provides all examinees with personalized health guidance of inheritance risk assessment and related disease risk aversion of DNA damage repair capacity. The method has the advantages that: an intervention measure can be taken before a gene damage happens, thereby avoiding the gene damage further to reduce the incidence of disease and the death rate of diseases such as tumor diseases related to the gene damage; the method analyzes a tumor pathogenic mechanism from a molecular mechanism, and can be used for the formulation of molecular cancer epidemiology investment and tumor prevention measures.

The invention discloses a kit for detecting the gastric cancer susceptibility, which is used for detecting four genes nearly concerned with gastric cancer as follows: MTHFR gene, CYP2E1 metabolic enzyme gene, XRCC1 and ADPRT repairase gene. The kit can simultaneously detect the following SNP (single nucleotide polymorphism) sites: the rs1801133 site of the MTHFR gene, the rs2031920 site of the CYP2E1, the rs25478 site of the XRCC1 gene and the rs1136410 site of the ADPRT gene. By using the kit disclosed by the invention, a group of genes and sites related to the gastric cancer susceptibility are detected, and whether the subject population carry gastric cancer susceptible genes can be judged clearly by using a specific primer and a specific probe by a mononucleotide extension technology combined with a microarray chip technology, thereby screening out the gastric cancer susceptible population from the subject population, changing unhealthy habits and customs and achieving the purpose of prevention.

The invention discloses a gene combination, a primer and a probe for detecting leukemia susceptibility and application. The gene combination comprises a combination of three genes closely related with leukemia, namely a CYP1A1 gene and an NQO1 gene of poison metabolism and an XRCC1 gene of DNA repair. The gene combination comprises the following SNP sites: rs464603 site of the CYP1A1 gene, rs1800566 site of the NQO1 gene, and rs1799782 and rs25487 sites of the XRCC1 gene. Whether the detected crowds carry 'leukemia susceptible genes' are comprehensively detected and analyzed by detecting a group of genes and sites related with the leukemia susceptibility, using the specific primer and the probe and combining a mononucleotide extending technique and a micro array chip technique so as to screen the leukemia susceptible crowd from the crowds, change unhealthy lifestyles and fulfill the purpose of preventing.

The invention relates to the technical field of molecular biology and particularly relates to a method and kit for detecting the polymorphism of an XRCC1 gene. The method comprises the following steps: (1) by adopting to-be-detected genomic DNA as a template, designing and synthesizing an upstream primer having the sequence as shown in SEQ ID NO: 1 and a downstream primer having the sequence as shown in SEQ ID NO: 2 and carrying out specific PCR amplification; (2) carrying out agarose gel electrophoresis on PCR amplification products and then carrying out gel recovery; and (3) sequencing the gel recovery products and comparing the sequencing results to determine the polymorphism of the gene. The primer pair used in the invention has stronger specificity, after the target gene is subjected to PCR amplification by virtue of the primer pair, the agarose gel electrophoresis is performed to obtain bands with very high teleonomy so that the success rate and reliability of the detection method are improved and the detection of polymorphic sites is of important significance for guiding individual treatment of cancer.

The invention discloses a kit for detecting susceptibility to leukemia. The kit is used for detecting three types of genes closely related to leukemia, namely CYP1A1 genes and NQO1 genes which are related to toxicant metabolization, and XRCC1 genes related to DNA restoration. SNP loci which can be detected simultaneously include rs4646903 loci of CYP1A1 genes, rs1800566 loci of NQO1, and rs1799782 and rs25487 loci of XRCC1. The kit is used, particularly a group of genes and loci which are related to the susceptibility to leukemia are detected, a primer with specificity and a probe are utilized and mononucleotide extension technology is adopted in combination with micro-array chip technology, so that whether persons to be detected carry 'leukemia susceptibility gene' or not can be judged, persons who are susceptible to leukemia are screened, bad living habits are changed and the prevention purpose is achieved.

The invention discloses a gene combination, a primer and a probe for detecting gastric cancer susceptibility and application. The gene combination comprises a combination of four genes closely related with a gastric cancer, namely an MTHFR gene, a CYP2E1 metabolic enzyme gene, an XRCC1 repairase gene and an ADPRT repairase gene. The gene combination comprises the following SNP sites: rs1801133 site of the MTHFR gene, rs2031920 site of the CYP2E1 gene, rs25478 site of the XRCC1 gene and rs1136410 site of the ADPRT gene. Whether the detected crowds carry 'gastric cancer susceptible genes' are comprehensively detected and analyzed by detecting a group of genes and sites related with the gastric cancer susceptibility, using the specific primer and the probe and combining a mononucleotide extending technique and a micro array chip technique so as to screen the gastric cancer susceptible crowd from the crowds, change unhealthy lifestyles and fulfill the purpose of preventing.

The invention discloses a kit that is used for detecting the genetic predisposition of wine and tobacco damages. The kit comprises particularity primer pairs and particularity fluorescent probe pairs that are used for simultaneously detecting 16 SNP polymorphism genotypes on the genes of ADH2, ALDH2, CYP1A1, CYP2A13, CYP2E1, ENOS, ERCC2, GSTM1, GSTP1, GSTT1, MTHFR, NQO1 and XRCC1 and a routine component that is used for fluorescent quantitative PCR detection, etc. The kit of the invention evaluates the genetic predisposition of wine and tobacco damages by simultaneously detecting the 16 mononucleotide polymorphism locus genotypes that are closely related with the genetic predisposition of wine and tobacco damages.

The invention discloses a kit for platinum drug medication guidance. The invention protects a primer group. The primer group comprises a primer pair A, a primer pair B and a primer pair C. The primer pair A comprises a single chain DNA molecule shown in the sequence 1 and a single chain DNA molecule shown in the sequence 2. The primer pair B comprises a single chain DNA molecule shown in the sequence 3 and a single chain DNA molecule shown in the sequence 4. The primer pair C comprises a single chain DNA molecule shown in the sequence 5 and a single chain DNA molecule shown in the sequence 6. The invention also protects a kit for identification of C118T point mutation of an ERCC1 gene, R194W point mutation of a XRCC1 gene and I105V point mutation of a GSTP1 gene. The kit comprises the primer group. The kit can be used for detecting three platinum drug sensitivity-related SNP sites, can be further used for platinum drug individual use guidance and improves clinical treatment specificity and predictability.

The present invention discloses a reagent kit to detect lung cancer susceptibility, which comprises a fluorescence probe to synchronously detect specificity tracers and specificity of No. rs25478 SNP locus on gene XRCC1 and No. rs1048943 SNP locus on gene CYP1A1, and a normal assembly to detect fluorescence quantitative PCR and so on. The reagent kit of the present invention synchronously detects and analyzes individual SNPs locus gene carrying type on gene XRCC1 and CYP1A1 to predict susceptibility of the individual to lung cancer.

The invention discloses a regent box for detecting the susceptibility to lung cancer, comprising a specific primer and a specific fluorescent probe which are capable of synchronously detecting an rs1136410 SNP locus on an PARP1 gene, an rs25487 SNP locus on a XRCC1 gene and an rs13181 SNP locus and an rs1799793 SNP locus on an ERCC2 gene, and common components for fluorescent quantitative detection of PCR. The reagent box of invention predicts the susceptibility to lung cancer of an individual by detecting the genotype of genes on the SNP loci of the PARP1 gene, the XRCC1 gene and the ERCC2 gene of the individual.

The invention discloses a reagent box for detecting lung cancer susceptibility. The reagent box comprises a pair of specificity primers for detecting concurrently no. rs25487 SNP site of XRCC1 gene and no. rs1799793 SNP site of ERCC2 gene, a specificity fluorescent probe and an ordinary assembly for fluorescent quantitative PCR detection. The reagent box predicts the susceptibility of individuals on lung cancer by detecting and analyzing currently the type of carried gene at SNPs site of individual XRCC1 and ERCC2 gene.

The present invention discloses a kit for detecting pulmonary carcinoma susceptibility. Said kit includes specific primer pair and specific fluorescent probe for detecting SNP site of position 156 in ERCC2 gene SEQ ID NO.1 and conventional component for making fluorescent quantitative PCR detection.

The invention discloses a reagent box for detecting lung cancer susceptibility. The reagent box comprises a pair of specificity primers for detecting concurrently no. rs25487 SNP site of XRCC1 gene and no. rs1136410 SNP site of PARP1 gene, a specificity fluorescent probe and an ordinary assembly for fluorescent quantitative PCR detection. The reagent box predicts the susceptibility of individuals on lung cancer by detecting and analyzing currently the type of carried gene at SNPs site of individual XRCC1 and PARP1 gene.

The invention belongs to the technical field of biological medicine and particularly relates to an application of XRCC1 gene polymorphism to rheumatoid arthritis diagnostic effectiveness and an application of SNP loci of the XRCC1 gene to preparation of a detection kit for diagnosing rheumatoid arthritis susceptibility. The correlation between polymorphism of the 641th lotus of the XRCC1 gene and rheumatoid arthritis is discovered for the first time, so that a method and a kit for detecting rheumatoid arthritis susceptibility risk through SNP are proposed on the basis, clinical experiment research verifies that the detection method has feasibility, and the detection kit has good sensitivity, stability and specificity.

The invention discloses a kind of reagent box for detection of susceptibility to esophageal cancer. The reagent box comprises of specific primer pairs for the detection of the 146th SNP locus in ERCC2 SEQ ID NO: 1 of XRCC1 gene, conventional components for fluorescence quantitative PCR. The reagent box by this invention can predict individual susceptibility to esophageal cancer through the detection of individual portable type of SNP locus gene in XRCC1 gene.

The invention provides a non-invasive detection kit for susceptibility gene of chronic lymphocytic leukemia. The kit comprises a specific primer and a DNA (Deoxyribonucleic Acid) sequencing primer which are used for detecting the genotypes of two single nucleotide polymorphic sites including an Arg399 Gln site on an XRCC1 (X-ray repair cross-complementing group 1) gene and an Lys751 Gln site on an XPD (xeroderma pigmentosum) gene, a PCR (Polymerase Chain Reaction) reaction component, a PCR product purification component and a DNA sequencing reaction component, etc. The kit disclosed by the invention is used for evaluating the suffering risk level of a chronic lymphocytic leukemia patient by detecting the genotypes of the two single nucleotide polymorphic sites closely related with appearance of chronic lymphocytic leukemia, and finally guiding the detected person to pointedly prevent occurrence of chronic lymphocytic leukemia from gene aspect according to the gene detection results of each detected person, thereby reducing the morbidity risk rate of chronic lymphocytic leukemia.

The present invention discloses a kit used for inspection of susceptibility of lung cancer. The kit comprises not only a specific primer couple and a specific fluorescent probe, which are capable of inspecting at the same time the site SNP of No. rs25487 of gene XRCC1, both the site SNP of No. rs13181 and the site SNP of No. rs1799793 of gene ERCC2, but also a standard component used for fluorescent quantitative PCR. The kit provided by the present invention predicts the individual susceptibility to lung cancer through mutual analysis on the gene type on the site of SNPs of both the gene XRCC1 and gene ERCC2.

The present invention discloses a reagent kit for detecting the susceptibility of the lung cancer. The reagent kit comprises a specific primer pair which detects the SNP locus of No. rs1136410 on a PARP1 gene, the SNP locus of No. rs1799793 on an ERCC2 gene and the SNP locus of No. rs25487 on a XRCC1 gene synchronously, a specific fluorescent probe, and a conventional component which is used for the fluorescent quantitative PCR detection, etc. The reagent kit of the present invention predicts the susceptibility of the individual to the lung cancer through detecting the gene carrying type of the SNPs loci on the PARP1 gene, the ERCC2 gene and the XRCC1 gene of the individual synchronously.

The present invention discloses a reagent kit for detecting the susceptibility of the lung cancer. The reagent kit comprises a specific primer pair which detects the SNP locus of No. rs1136410 on a PARP1 gene, the SNP locus of No. rs13181 and the SNP locus of No. rs1799793 on an ERCC2 gene synchronously, a specific fluorescent probe, and a conventional component which is used for the fluorescent quantitative PCR detection, etc. The reagent kit of the present invention predicts the susceptibility of the individual to the lung cancer through detecting the gene carrying type of the SNPs loci on the PARP1 gene, the ERCC2 gene and the XRCC1 gene of the individual synchronously.

The invention discloses a rapid testing method for main polymorphism site of repair protein gene (XRCC1) of human ribonucleotide. According to designed primers of genetic DNA sequence of human chromosome XRCC1, the invention employs polymerase chain reaction (PCR) specific technique to amplify a fragment of DNA sequence respectively including mutation sites of R194W, R280H and R399Q, respectively uses a pair of molecular fluorescent probes to be hybridized with amplified product. Whether a sample includes mutation of R194W, R280H and R399Q is tested by real-time detection of a fluorescent PCR instrument to corresponding specific fluorescent intensity alternation of reaction tubes or by direct detection of specific fluorescent intensity of reaction tubes via a fluorescence spectrophotometer after PCR. The method is convenient and rapid, high in specificity, economic and practical, which is applicable for rapid detection of large-scaled samples. The invention further provides kits applicable for clinical application.

The invention provides a thyroid cancer susceptibility gene detection kit, which comprises specific primers for detecting XRCC1 gene Arg399Gln locus and hMSH2 gene 13th exon sequence, DNA sequencing primers, a PCR reaction assembly and the like. According to the present invention, the thyroid cancer susceptibility risk levels of subjects are evaluated by detecting the information of the genes XRCC1 and hMSH2 closely related to the occurrence of thyroid cancer, and according to the gene detection results of each subject, the subjects can be guided with the targeted prevention of the occurrenceof thyroid cancer so as to reduce the incidence of thyroid cancer; and the detection result is accurate and reliable, and the method is easy to popularize.

The present invention discloses a reagent kit for detecting the susceptibility of the lung cancer. The reagent kit comprises a specific primer pair which detects the SNP locus of No. rs1136410 on a PARP1 gene, the SNP locus of No. rs13181 on an ERCC2 gene and the SNP locus of No. rs25487 on a XRCC1 gene synchronously, a specific fluorescent probe, and a conventional component which is used for the fluorescent quantitative PCR detection, etc. The reagent kit of the present invention predicts the susceptibility of the individual to the lung cancer through detecting the gene carrying type of the SNPs loci on the PARP1 gene, the ERCC2 gene and the XRCC1 gene of the individual synchronously.

The invention discloses a reagent kit for detecting lung cancer susceptibility, comprising a common component for fluorescence quantitative PCR detection, and a specific primer pair and a specific fluorescent probe which detect the NO. rs1136410 SNP site of PARP1 gene, the NO. rs1048943 SNP site of CYP1A1 gene, the NO. rs25487 SNP site of XRCC1 gene and the NO. rs13181 SNP site of ERCC2 gene at the same time. The reagent kit can predict the lung cancer susceptibility of individual through detecting the SNPs site genotype of PARP1 gene, CYP1A1 gene, XRCC1 gene and ERCC2 gene of individual at the same time.

The invention discloses a reagent box for detecting lung cancer susceptibility. The reagent box comprises a pair of specificity primers for detecting concurrently no. rs25487 SNP site of XRCC1 gene and no. rs13181 SNP site of ERCC2 gene, a specificity fluorescent probe and an ordinary assembly for fluorescent quantitative PCR detection. The reagent box predicts the susceptibility of individuals on lung cancer by detecting and analyzing currently the type of carried gene at SNPs site of individual XRCC1 and ERCC2 gene.